Maxim Group

Steakholder Foods Ltd is a deep-tech food company focused on revolutionizing protein manufacturing through innovative 3D printing technologies. The company is dedicated to creating sustainable and high-quality alternative meat and seafood products that closely mimic the taste and texture of traditional proteins. By developing proprietary three-dimensional bioprinting techniques, Steakholder aims to improve meat production, streamline the supply chain, and provide consumers with a diverse range of offerings. Its mission includes reducing the environmental impact of food production by minimizing carbon footprints, water usage, and land requirements, while also eliminating the need for animal slaughter. Through its advanced manufacturing solutions, Steakholder Foods is positioning itself as a leader in the plant-based and cultivated meat industry, committed to supporting partners in the rapidly evolving market.

Nacuity Pharmaceuticals, based in Fort Worth, Texas, is a biotechnology company focused on developing innovative treatments for retinitis pigmentosa and other ophthalmological disorders. Established in 2016, the company is dedicated to addressing ocular oxidative stress and aims to provide effective therapies for patients affected by various retinal diseases. Nacuity has garnered significant financial and technical backing from the Foundation Fighting Blindness, which has invested nearly $700 million over the past 46 years to support research into preventing and treating blinding retinal diseases. The Foundation is a key partner in advancing Nacuity’s development program, particularly through its commitment to fund a substantial portion of the company's Phase 1 and Phase 2 clinical trials via a milestone-based matching grant.

Alveo Technologies, Inc., established in 2014 and based in Alameda, California, specializes in developing infectious disease diagnostic devices. The company's flagship product, be.well, is a comprehensive system that includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. This integrated platform combines nucleic acid detection with molecular biochemistry to identify illnesses such as Flu A/B, COVID-19, and RSV. By leveraging advances in sensing, microfluidics, and bioassays, Alveo aims to empower consumers, healthcare professionals, and treatment providers with early and accurate diagnostic information, facilitating better-informed decisions and improved patient outcomes.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops therapies for Batten disease, cystic fibrosis, and genetic eye disorders. Additionally, Abeona Therapeutics is advancing the AIM Vector Platform, which includes over 100 next-generation AAV capsids for delivering gene therapies to various organs. The company operates a manufacturing facility producing therapies and vectors for preclinical and clinical studies.

Edge Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for acute neurological conditions, particularly in hospital settings. Founded in 2009 and based in Berkeley Heights, New Jersey, the company aims to transform treatment paradigms for serious medical conditions with significant unmet needs. Its lead product candidate, EG-1962, is currently being evaluated in the Phase 3 NEWTON 2 study for the treatment of aneurysmal subarachnoid hemorrhage, a condition resulting from bleeding around the brain due to a ruptured aneurysm. Additionally, Edge is developing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aiming to prevent recurrent bleeding on the brain's surface. The company employs its proprietary Precisa platform to create polymer-based therapeutics that deliver treatment directly to the site of injury, minimizing impact on surrounding tissues.

ContraFect Corporation is a clinical-stage biotechnology firm based in Yonkers, New York, specializing in the development of therapeutic proteins and antibodies for the treatment of life-threatening, drug-resistant infectious diseases. The company's lead candidate, CF-301, is a novel lysin currently undergoing Phase III clinical trials for staphylococcus aureus bacteremia, including endocarditis. ContraFect is also advancing CF-296, an engineered lysin targeting invasive staphylococcal infections, and CF-370, an investigational therapy in preclinical stages aimed at treating infections caused by pseudomonas aeruginosa. The company has a research collaboration with The Rockefeller University to identify novel lysin candidates targeting gram-negative pathogens. Additionally, ContraFect has initiated an expanded access program for exebacase, intended for patients with persistent bacteremia linked to methicillin-resistant Staphylococcus aureus in COVID-19 cases. Founded in 2008, ContraFect aims to address the challenges posed by multi-drug resistant infections through its innovative treatments.

BillMyParents delivers SuperSafe payment solutions that allow teens greater financial freedom, while giving parents the ability to easily track and control their spending. BillMyParents Supervised Shopping - With a simple email request and approval system, provides the independence young people crave and the control over spending that parents want - while ensuring that credit card numbers and personal information are kept safe and secure. BillMyParents is currently available as a payment solution at select online retail stores, in addition to social network, virtual worlds and online gaming web sites. The teen prepaid MasterCard extends BillMyParents into the offline world, the BillMyParents MasterCard Prepaid Card is accepted anywhere MasterCard debit cards are accepted and offers teens more options than ever before, meanwhile it provides advanced parental controls and spending insight that makes it a far superior option for parents than giving cash or sharing their own credit card information for purchases. Its Peace of Mind Control Panel provides the following parental benefits: - The ability to monitor transactions in real-time via email and/or SMS notifications - Instant lock / unlock of their teen’s card - Instant emergency funding for the teen — so they are never stranded without access to money in an emergency - Lost card protection (losing the card doesn’t lose the value on the card) - No credit implications for parents or their teens - No overdraft fees!